XML 38 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:      
Net loss $ (130,391) $ (133,310) $ (36,329)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 5,725 5,714 6,329
Stock-based compensation 42,798 46,146 40,785
Amortization of premiums and accretion of discounts on marketable securities (15,318) (1,163) 2,099
Amortization of right-of-use assets 3,123 2,758 1,986
Loss from disposal of fixed assets 48 0 0
Changes in operating assets and liabilities:      
Receivable from collaboration partner 2,587 4,804 (7,391)
Prepaid expenses and other current assets (5,949) (3,926) 1,132
Other assets (1,009) (835) (2,957)
Accounts payable (377) (572) 1,917
Accrued liabilities and accrued clinical supply costs 2,546 (2,655) 2,391
Payable to collaboration partner 7,703 0 0
Deferred revenue (66,782) 66,383 292,915
Refund liability to collaboration partner (24,512) 0 0
Lease liabilities (4,968) (4,274) (4,012)
Other long-term liabilities 614 601 (314)
Net cash provided by (used in) operating activities (184,162) (20,329) 298,551
Cash flows from investing activities:      
Purchase of property and equipment (2,381) (4,117) (3,247)
Purchase of marketable securities (551,729) (556,898) (343,402)
Maturities of marketable securities 652,523 402,001 286,290
Sale of marketable securities 3,505 0 10,696
Net cash provided by (used in) investing activities 101,918 (159,014) (49,663)
Cash flows from financing activities:      
Proceeds from the exercise of options to purchase common stock 1,079 3,059 28,530
Proceeds from issuance of stock from employee stock purchase plan 1,471 1,455 1,765
Net cash provided by financing activities 2,550 4,514 30,295
Net increase (decrease) in cash, cash equivalents, and restricted cash (79,694) (174,829) 279,183
Cash, cash equivalents, and restricted cash at beginning of period 155,795 330,624 51,441
Cash, cash equivalents, and restricted cash at end of period 76,101 155,795 330,624
Non-cash investing and financing activities:      
Property and equipment purchases included in accounts payable and accrued liabilities $ 172 $ 493 $ 705